1. EMEA: for patients or for industry?

   • Silvio Garattini

   Editorial 17 September 2012 Pages: 207 - 208

2. The relationship between productivity and health-related QOL

   • Werner B. F. Brouwer
   • Willem-Jan Meerding
   • Johan L. Severens

   Current Opinion 17 September 2012 Pages: 209 - 218

   

3. Penny and pound wise

   • Mike F. van Oostenbruggen
   • Ronald B. Jansen
   • Huib Kooijman

   Current Opinion 17 September 2012 Pages: 219 - 226

   

4. The economic impact of neuropsychiatric symptoms in Alzheimer’s disease

   • Daniel L. Murman
   • Christopher C. Colenda

   Leading Article 17 September 2012 Pages: 227 - 242

   

5. International variation in resource utilisation and treatment costs for rheumatoid arthritis

   • Hubertus Rosery
   • Rito Bergemann
   • Stefanie Maxion-Bergemann

   Review Article 17 September 2012 Pages: 243 - 257

   

6. Oral serotonin receptor agonists

   • Jennifer H. Lofland
   • David B. Nash

   Review Article 17 September 2012 Pages: 259 - 274

   

7. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain

   • Pedro J. Tárraga-López
   • Ángel Celada-Rodríguez
   • Jaime De Miguel-Clave

   Original Research Article 17 September 2012 Pages: 275 - 287

   

8. The case of tumour necrosis factor-α inhibitors in the treatment of rheumatoid arthritis

   • Jan Sørensen
   • Lis S. Andersen

   Original Research Article 17 September 2012 Pages: 289 - 298

   

9. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US

   • Natalie C. Edwards
   • Marcia F. T. Rupnow
   • Ronald J. Diamond

   Original Research Article 17 September 2012 Pages: 299 - 314